| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Kostewicz, Edmund S., et al.
(författare)
-
PBPK models for the prediction of in vivo performance of oral dosage forms
- 2014
-
Ingår i: European Journal of Pharmaceutical Sciences. - : Elsevier BV. - 0928-0987 .- 1879-0720. ; 57:SI, s. 300-321
-
Forskningsöversikt (refereegranskat)abstract
- Drug absorption from the gastrointestinal (GI) tract is a highly complex process dependent upon numerous factors including the physicochemical properties of the drug, characteristics of the formulation and interplay with the underlying physiological properties of the GI tract. The ability to accurately predict oral drug absorption during drug product development is becoming more relevant given the current challenges facing the pharmaceutical industry. Physiologically-based pharmacokinetic (PBPK) modeling provides an approach that enables the plasma concentration time profiles to be predicted from preclinical in vitro and in vivo data and can thus provide a valuable resource to support decisions at various stages of the drug development process. Whilst there have been quite a few successes with PBPK models identifying key issues in the development of new drugs in vivo, there are still many aspects that need to be addressed in order to maximize the utility of the PBPK models to predict drug absorption, including improving our understanding of conditions in the lower small intestine and colon, taking the influence of disease on GI physiology into account and further exploring the reasons behind population variability. Importantly, there is also a need to create more appropriate in vitro models for testing dosage form performance and to streamline data input from these into the PBPK models. As part of the Oral Biopharmaceutical Tools (OrBiTo) project, this review provides a summary of the current status of PBPK models available. The current challenges in PBPK set-ups for oral drug absorption including the composition of GI luminal contents, transit and hydrodynamics, permeability and intestinal wall metabolism are discussed in detail. Further, the challenges regarding the appropriate integration of results from in vitro models, such as consideration of appropriate integration! estimation of solubility and the complexity of the in vitro release and precipitation data, are also highlighted as important steps to advancing the application of PBPK models in drug development. It is expected that the "innovative" integration of in vitro data from more appropriate in vitro models and the enhancement of the GI physiology component of PBPK models, arising from the OrBiTo project, will lead to a significant enhancement in the ability of PBPK models to successfully predict oral drug absorption and advance their role in preclinical and clinical development, as well as for regulatory applications.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Silvergren, Sanna, et al.
(författare)
-
Hygroscopic growth and cloud forming potential of Arctic aerosol based on observed chemical and physical characteristics (a 1 year study 2007-2008)
- 2014
-
Ingår i: Journal of Geophysical Research - Atmospheres. - 2169-897X .- 2169-8996. ; 119:24, s. 14080-14097
-
Tidskriftsartikel (refereegranskat)abstract
- Aerosol particle samples were collected, and the particle size distribution was measured during 1 year at the Zeppelin station (474 m asl) on Svalbard. The chemical constituents, hygroscopicity, and cloud forming properties of the aerosol were analyzed. The aerosol contained mostly sulfate and nitrate during the summer, whereas from September to February the main components were sodium and chloride. The highest concentration (20%) of water-soluble organic matter was sampled in December. The hygroscopic growth factors for the water-soluble fraction were 1.56-2.01 at 90% relative humidity, peaking in October, when the measured supersaturations needed for cloud drop formation were also the lowest. Sea-salt components showed a positive correlation with the cloud forming capability, whereas the organic content had no correlation. The hygroscopicity factors, or kappa values, were determined in three ways for each month: (1)kappa(H-TDMA) from measurements of the hygroscopic growth of particles produced from atomization of the filter extracts, (2)kappa(CCNC) from measurements of the critical supersaturation as a function of size for these particles, and (3)kappa(chem) was modeled based on the organic and inorganic composition of the filter samples. Using the measured particle size distributions and the critical activation diameters from the Cloud Condensation Nuclei Counter (CCNC) measurements, it was found that the number of CCN varied more with supersaturation during the summer months. The best agreement between all three kappa values was in December and January. Comparisons with earlier studies do not suggest any trend in the Arctic aerosol seasonal variability over the last decade.
|
|
| 9. |
|
|
| 10. |
|
|
